Liver fibrosis remains a significant public health problem. However, few drugs have yet been validated. Costunolide (COS), as a monomeric component of the traditional Chinese medicinal herb , has shown excellent anti-fibrotic efficacy. However, COS displays very poor aqueous solubility and poor stability in gastric juice, which greatly limits its application via an oral administration. To increase the stability, improve the dissolution rate and enhance the anti-liver fibrosis of COS, pH-responsive mesoporous silica nanoparticles (MSNs) were selected as a drug carrier. Methacrylic acid copolymer (MAC) as a pH-sensitive material was used to coat the surface of MSNs. The drug release behavior and anti-liver fibrosis effects of MSNs-COS-MAC were evaluated. The results showed that MSNs-COS-MAC prevented a release in the gastric fluid and enhanced the dissolution rate of COS in the intestinal juice. At half the dose of COS, MSNs-COS-MAC still effectively ameliorated parenchymal necrosis, bile duct proliferation and excessive collagen. MSNs-COS-MAC significantly repressed hepatic fibrogenesis by decreasing the expression of hepatic fibrogenic markers in LX-2 cells and liver tissue. These results suggest that MSNs-COS-MAC shows great promise for anti-liver fibrosis treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539632 | PMC |
| http://dx.doi.org/10.3390/ph14100951 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Natural small molecule hinokitone mitigates NASH fibrosis by targeting regulation of FXR-mediated hepatocyte apoptosis.
J Adv Res
December 2024
Department of Pharmacology, School of Basic Medical Sciences, Peking University Health Science Center, 38 Xueyuan Road, Haidian District, Beijing 100191, China; State Key Laboratory of Vascular Homeostasis and Remodeling, State Key Laboratory of Natural and Biomimetic Drugs, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Peking University, Beijing 100191, China; Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, Beijing 100191, China. Electronic address:
Introduction: Liver fibrosis is the common fate of NASH and poses a major health threat with very limited pharmacological treatments.
Objectives: This study aims to investigate the preventive effect of hinokitone (HO), an isolated compound from Agathis dammara, on NASH fibrosis and its underlying mechanism.
Methods: To investigate the effect of HO on NASH fibrosis, C57BL/6 mice were either fed a high-fat diet (HFD) in conjunction with intraperitoneal injection of CCl for 8 weeks or single CCl for 14 days to establish mouse liver fibrosis model, and HO was administered by gavage simultaneously.
Study on the Hepatotoxicity of Emodin and Its Application in the Treatment of Liver Fibrosis.
Molecules
October 2024
State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Article Synopsis
- Emodin (EMO) is a compound with notable pharmacological benefits but has been linked to liver toxicity, prompting research into its safer application.
- The study combined EMO with tetrandrine to create lipid nanoparticles (E-T/LNPs) and tested their effectiveness and safety in zebrafish and mice, revealing that E-T/LNPs have a stable structure and better therapeutic potential.
- Results indicated that E-T/LNPs can effectively treat liver fibrosis at low doses while reducing EMO's toxicity, partly by lowering inflammatory markers in the liver.
Design and Synthesis of Dual Galectin-3 and EGFR Inhibitors Against Liver Fibrosis.
Chem Asian J
November 2024
Henan Polysaccharide Research Center, Henan Key Laboratory of Chinese Medicine for Polysaccharides and Drugs Research, Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, 450046, China.
Liver fibrosis, mainly arising from chronic viral or metabolic liver diseases, is a significant global health concern. There is currently only one FDA-approved drug (Resmetirom) in the market to combat liver fibrosis. Both galectin-3 and epidermal growth factor receptor (EGFR) play important roles in liver fibrosis, while galectin-3 may interact with EGFR.
View Article and Find Full Text PDFSynthesis and Anti-Liver Fibrosis Research of Aspartic Acid Derivatives.
Molecules
October 2024
Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Article Synopsis
- Liver fibrosis is a significant factor in liver disease progression, but effective drugs to treat it are lacking.
- Researchers developed 32 new compounds based on aspartic acid, with 22 being unique, and tested their ability to inhibit liver fibrosis.
- Four compounds showed impressive inhibition rates, and two were effective in reducing key fibrosis markers and inflammation through a specific signaling pathway, paving the way for new treatments.
The processing mechanism of vinegar-processed Curcumae Rhizome enhances anti hepatic fibrotic effects through regulation of PI3K/Akt/mTOR signaling pathway.
Phytomedicine
December 2024
College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China. Electronic address:
Article Synopsis
- Hepatic fibrosis is a serious liver condition that can lead to cirrhosis and liver cancer, and vinegar-processed Curcumae Rhizoma (VCR) is traditionally used in Chinese medicine to treat related diseases.
- The study analyzed the anti-liver fibrosis effects of both unprocessed Curcumae Rhizoma (CR) and VCR, with VCR showing improved therapeutic outcomes due to vinegar processing and specific bioactive compounds.
- Results indicated that VCR significantly lessened liver damage, reduced lipid buildup, and lowered liver function markers, suggesting enhanced efficacy in treating hepatic fibrosis through network pharmacology and metabolomic analyses.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!